Payment overview · 2025
General Payments
$130.08
7 reported records · 5 companies
Healthcare provider profile · identity verified
Audrey K Montooth, MD
Allopathic & Osteopathic Physicians|Family Medicine · SAINT LOUIS, MO · NPI 1730132895
Verified facts
What the public records show
CMS Open Payments records show Audrey K Montooth, MD received $130.08 in general payments during 2025 across 7 reported records.
PFIZER INC. accounted for 26.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Prolia by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.91 | 26.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.80 | 25.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.41 | 22.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $17.26 | 13.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.70 | 12.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $130.08 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $29.41 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.68 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.68 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $17.26 | 1 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.18 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $14.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 169 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 112 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
22 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
112 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
169 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 489 | 140 |
| Amlodipine Besylate | Amlodipine Besylate | 432 | 122 |
| Atorvastatin Calcium | Atorvastatin Calcium | 425 | 116 |
| Levothyroxine Sodium | Levothyroxine Sodium | 343 | 88 |
| Lisinopril | Lisinopril | 312 | 87 |
| Losartan Potassium | Losartan Potassium | 296 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 252 | 67 |
| Eliquis | Apixaban | 169 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 165 | 49 |
| Alendronate Sodium | Alendronate Sodium | 164 | 49 |
| Omeprazole | Omeprazole | 152 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 150 | 45 |
| Metformin Hcl | Metformin Hcl | 150 | 44 |
| Metformin Hcl Er | Metformin Hcl | 142 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 138 | 59 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 121 | 52 |
| Furosemide | Furosemide | 119 | 32 |
| Ozempic | Semaglutide | 112 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 104 | 32 |
| Gabapentin | Gabapentin | 103 | 31 |
| Trazodone Hcl | Trazodone Hcl | 102 | 34 |
| Sertraline Hcl | Sertraline Hcl | 101 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 94 | 27 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 92 | 92 |
| Simvastatin | Simvastatin | 84 | 25 |
| Lovastatin | Lovastatin | 81 | 22 |
| Tramadol Hcl | Tramadol Hcl | 75 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 73 | 21 |
| Famotidine | Famotidine | 72 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 68 | 20 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 68 | 24 |
| Meloxicam | Meloxicam | 66 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 65 | 18 |
| Allopurinol | Allopurinol | 64 | 16 |
| Carvedilol | Carvedilol | 63 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 63 | 15 |
| Prednisone | Prednisone | 63 | 36 |
| Folic Acid | Folic Acid | 60 | 21 |
| Potassium Chloride | Potassium Chloride | 56 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 16 |
| Buprenorphine | Buprenorphine | 50 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | 12 |
| Ezetimibe | Ezetimibe | 49 | 11 |
| Lorazepam | Lorazepam | 44 | 18 |
| Mounjaro | Tirzepatide | 42 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 41 | suppressed |
| Jardiance | Empagliflozin | 40 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 40 | 12 |
| Mirtazapine | Mirtazapine | 39 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 39 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 37 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 36 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 28 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 35 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Benzonatate | Benzonatate | 33 | 23 |
| Valsartan | Valsartan | 31 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | 12 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 28 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 28 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 27 | suppressed |
| Temazepam | Temazepam | 27 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 20 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Prolia | Denosumab | 22 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Ketoconazole | Ketoconazole | 20 | 14 |
| Mirabegron Er | Mirabegron | 20 | suppressed |
| Alprazolam | Alprazolam | 19 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 19 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Azithromycin | Azithromycin | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $130.08 · 7 records | PFIZER INC. | ELIQUIS, LEQVIO, NURTEC ODT, Ozempic, QULIPTA, TAVNEOS, VYNDAQEL, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error